Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)

被引：0
作者：
Yap, Y. S. [1 ]
Masuda, N. [2 ]
Ito, Y. [3 ]
Ishikawa, T. [4 ]
Kim, S. J. [5 ]
Aruga, T. [6 ]
Toyama, T. [7 ]
Saeki, T. [8 ]
Yamanaka, T. [9 ]
Saito, M. [10 ]
Watanabe, J. [11 ]
Takahashi, M. [12 ]
Nakamura, S. [13 ]
Inoue, K. [14 ]
Suarez-Vizcarra, J. [15 ]
He, W. [15 ]
Solovieff, N. [16 ]
Su, F. [15 ]
Chiu, J. [17 ]
机构：
[1] Natl Canc Ctr, Med Oncol, Singapore, Singapore
[2] Osaka Natl Hosp, Med Oncol, Osaka, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Med Oncol, Tokyo, Japan
[4] Tokyo Med Univ Hosp, Med Oncol, Tokyo, Japan
[5] Osaka Univ Hosp, Med Oncol, Osaka, Japan
[6] Tokyo Komagome Hosp, Med Oncol, Tokyo, Japan
[7] Nagoya City Univ, Grad Sch Med Sci, Med Oncol, Nagoya, Aichi, Japan
[8] Saitama Med Univ, Med Oncol, Int Med Ctr, Saitama, Japan
[9] Kanagawa Canc Ctr, Med Oncol, Yokohama, Kanagawa, Japan
[10] Juntendo Univ Hosp, Med Oncol, Tokyo, Japan
[11] Shizuoka Canc Ctr, Med Oncol, Nagaizumi, Shizuoka, Japan
[12] Hokkaido Canc Ctr, Natl Hosp Org, Med Oncol, Sapporo, Hokkaido, Japan
[13] Showa Univ Hosp, Breast Ctr, Tokyo, Japan
[14] Saitama Canc Ctr, Med Oncol, Saitama, Japan
[15] Novartis Pharmaceut, Novartis Oncol, E Hanover, NJ USA
[16] Novartis Inst BioMed Res, Biomarkers & Diagnost Biometr, Cambridge, MA USA
[17] Queen Mary Hosp, Med Oncol, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
10.1093/annonc/mdy428
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
400
引用
收藏
页码：13 / +
页数：2
相关论文
共 50 条
  • [31] The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
    Aapro, Matti
    De Laurentiis, Michelino
    Rea, Dan
    Bargallo Rocha, Juan Enrique
    Elizalde, Roberto
    Landherr, Laszlo
    Linderholm, Barbro
    Mamounas, Eleftherios
    Markopoulos, Christos
    Neven, Patrick
    Petrovsky, Alexander
    Rouzier, Roman
    Smit, Vincent
    Svedman, Christer
    Schneider, Daniel
    Thomssen, Christoph
    Martin, Miguel
    [J]. BREAST, 2017, 33 : 191 - 199
  • [32] Addition of Ribociclib to Endocrine Therapy Improves Outcomes in EarlyStage, HR+/HER2- Breast Cancer
    Rugo, Hope S.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 352 - 352
  • [33] A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer
    Alemany, Carlos
    Patel, Manish
    Mitri, Zahi
    Sparano, Joseph
    Borges, Virginia
    Makower, Della
    Klein, Pam
    Lawrence, Julia
    Le, Trinh
    Zujewski, Jo Anne
    Harmilton, Erika
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [34] BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib plus letrozole and on second-line treatment with alpelisib plus fulvestrant
    Allegrini, G.
    Orditura, M.
    Del Mastro, L.
    Zamagni, C.
    Torrisi, R.
    Guarneri, V.
    Paris, I.
    Sarobba, G.
    Puglisi, F.
    Colleoni, M. A.
    Montemurro, F.
    Zambelli, A.
    Cazzaniga, M. E.
    Valerio, M. R.
    Bianchi, G.
    Romagnoli, E.
    Caruso, M.
    Cinieri, S.
    Castelletti, D.
    Arpino, G.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S302 - S302
  • [35] FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
    Shah, Anand
    Bloomquist, Erik
    Tang, Shenghui
    Fu, Wentao
    Bi, Youwei
    Liu, Qi
    Yu, Jingyu
    Zhao, Ping
    Palmby, Todd R.
    Goldberg, Kirsten B.
    Chang, C. J. George
    Patel, Paresma
    Alebachew, Elleni
    Tilley, Amy
    Pierce, William F.
    Ibrahim, Amna
    Blumenthal, Gideon M.
    Sridhara, Rajeshwari
    Beaver, Julia A.
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (13) : 2999 - 3004
  • [36] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [37] HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)
    Pascual, T.
    Stover, D. G.
    Thuerigen, A.
    Perou, C. M.
    Ciruelos, E. M.
    Fernandez Tejerina, A. Casas
    Spears, P.
    Roux, E.
    Hu, H.
    Lu, Y-S.
    Tolaney, S. M.
    Partridge, A.
    Villacampa Javierre, G.
    Ferrero Cafiero, J. M.
    Carey, L.
    Prat, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S662 - S662
  • [38] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    [J]. CANCER TREATMENT REVIEWS, 2024, 123
  • [39] Ribociclib in HR-positive, HER2-negative breast cancer
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2016, 17 (11) : E482 - E482
  • [40] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    [J]. FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
12345